The World Health Organization (WHO) convenes expert and advisory groups to review potential vaccines and therapeutics for Ebola disease caused by the Bundibugyo virus (BVD) during the current outbreak in the Democratic Republic of the Congo. The outbreak is also reported to have cases in Uganda. According to WHO, the expert groups assess candidate products intended for both prevention and treatment of BVD. These assessments focus on determining which candidates could be used to generate evidence during the outbreak response. The outlets reporting on WHO’s convening of these groups state that the products identified and considered should be used only within clinical trials, to produce robust data on safety and effectiveness. The WHO process reflects an effort to guide research and clinical decision-making while limiting deployment of unproven interventions outside structured studies. Overall, WHO’s advisory work centers on evaluating available candidates and emphasizing that any use of these products should occur through clinical trial frameworks to support reliable conclusions.